Agilon health’s second quarter was marked by a significant revenue shortfall and a sharply negative market reaction. Management attributed the underperformance to weaker-than-expected risk adjustment revenue and lingering challenges in its Part D business. Executive Chair Ronald Williams described the results as disappointing, emphasizing that both industry headwinds and internal execution gaps contributed to the quarter’s outcome. The leadership transition, with Williams stepping in as Executive Chairman and CEO Steven Sell’s departure, signals an urgent focus on operational improvement and cost discipline as the company navigates a volatile healthcare environment.

Is now the time to buy AGL? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From agilon health’s Q2 Earnings Call

• Elizabeth Hammell Anderson (Evercore): Asked if positive prior year development (PYD) could occur in Q3 and about future growth strategy amid cost trend uncertainties. CFO Jeffrey Schwaneke confirmed growth is under review and near-term focus is on profitability.
• Eduardo Enrique Ron (Truist): Inquired about sequential cost trends and the consistency of risk adjustment estimates across agilon’s book. Schwaneke noted cost trends were consistent and explained that variability among payers prevented extrapolation across the full membership.
• Justin Lake (Wolfe Research): Questioned the outlook for 2026 payer bids and the willingness to exit payer relationships if economics do not improve. Schwaneke highlighted ongoing negotiations and a readiness to walk away from unfavorable deals.
• Ryan M. Langston (TD Cowen): Sought clarity on what qualities are needed in the next CEO and the potential for further partnership exits. Williams outlined the need for operating rigor and multi-market experience, while Schwaneke said partner exits are under ongoing evaluation.
• Matthew Dineen Shea (Needham): Asked about the durability of quality incentive benefits and payers’ willingness to include more quality-based metrics in contracts. Schwaneke responded that payers are increasing dollars allocated to quality, which aligns well with agilon’s strengths.

Catalysts in Upcoming Quarters

In the coming quarters, StockStory analysts will be monitoring (1) the pace and outcome of contract renewals with payer partners, which will be crucial for 2026 profitability; (2) execution on reducing exposure to Part D and other volatile revenue streams; and (3) tangible improvements in operational efficiency and clinical program expansion. Progress on CEO recruitment and the ability to maintain strong physician partnership retention will also be pivotal for agilon’s turnaround.

agilon health currently trades at $0.90, down from $1.82 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

The Best Stocks for High-Quality Investors

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.